Long-term effects of weight-reducing drugs in people with hypertension.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD007654.pub4PMID 26934640
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacological management of obesity: an endocrine Society clinical practice guideline.

  2015cited by this paper
• Weight loss effect of glucagon‐like peptide‐1 mimetics on obese/overweight adults without diabetes: A systematic review and meta‐analysis of randomized controlled trials胰高血糖素样肽‐1类似物对非糖尿病肥胖/超重成人的减重作用：一篇对随机对照试验进行的系统评价及meta分析

  2015cited by this paper
• 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).

  2014cited by this paper
• Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release

  2014cited by this paper
• The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

  2014cited by this paper
• Long-term drug treatment for obesity: a systematic and clinical review.

  2014cited by this paper
• Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease

  2014cited by this paper
• Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date

  2014cited by this paper
• 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension

  2014cited by this paper
• Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.

  2013cited by this paper
• A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II)

  2013cited by this paper
• Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2).

  2013cited by this paper
• Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes

  2013cited by this paper
• Efficacy and safety of lorcaserin in obese adults: a meta‐analysis of 1‐year randomized controlled trials (RCTs) and narrative review on short‐term RCTs

  2013cited by this paper
• Evaluation of phentermine and topiramate versus phentermine/topiramate extended‐release in obese adults

  2013cited by this paper
• Randomized Placebo‐Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM‐DM Study

  2012cited by this paper
• A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.

  2012cited by this paper
• Does rimonabant independently affect free fatty acid and glucose metabolism?

  2012cited by this paper
• Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR‐BMOD Trial

  2011cited by this paper
• Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

  2011cited by this paper
• A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.

  2011cited by this paper
• Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.

  2011cited by this paper
• Glucagon-like peptide analogues for type 2 diabetes mellitus.

  2011cited by this paper
• Evaluation of efficacy and safety of orlistat in obese patients

  2011cited by this paper
• Effect of rimonabant on carotid intima–media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial

  2011cited by this paper
• Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients

  2011cited by this paper
• Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)

  2011cited by this paper
• Multicenter, placebo-controlled trial of lorcaserin for weight management.

  2010cited by this paper
• Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients.

  2010cited by this paper
• Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.

  2010cited by this paper
• Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

  2010cited by this paper
• Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.

  2010cited by this paper
• Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue.

  2009cited by this paper
• Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.

  2009cited by this paper
• Effect of diet-induced weight loss on plasma apelin and cytokine levels in individuals with the metabolic syndrome.

  2009cited by this paper
• Long-term effects of weight-reducing drugs in hypertensive patients.

  2009cited by this paper
• Effect of Rimonabant on the High-Triglyceride/Low–HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat: The ADAGIO-Lipids Trial

  2009cited by this paper
• Long-term effects of weight-reducing drugs in hypertensive patients.

  2009cited by this paper
• Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects.

  2009cited by this paper
• A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.

  2009cited by this paper
• Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.

  2008cited by this paper
• Tolerability of Sibutramine During a 6-week Treatment Period in High-Risk Patients With Cardiovascular Disease and/or Diabetes: A Preliminary Analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial

  2008cited by this paper
• Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis.

  2008cited by this paper
• Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.

  2008cited by this paper
• Effect of Orlistat on Eating Behavior Among Participants in a 3‐year Weight Maintenance Trial

  2008cited by this paper
• Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.

  2008cited by this paper
• Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.

  2007cited by this paper
• Long term pharmacotherapy for obesity and overweight: updated meta-analysis

  2007cited by this paper
• Drug treatments for obesity: orlistat, sibutramine, and rimonabant.

  2007cited by this paper
• Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

  2006cited by this paper
• Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

  2006cited by this paper
• Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients

  2005cited by this paper
• Effects of Weight Loss in Overweight/Obese Individuals and Long-Term Hypertension Outcomes: A Systematic Review

  2005cited by this paper
• Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes

  2005cited by this paper
• Effect of orlistat on cardiovascular disease risk in obese adults

  2005cited by this paper
• Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

  2005cited by this paper
• [Efficacy and safety of a short-time orlistat treatment in obese subjects].

  2005cited by this paper
• Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

  2005cited by this paper
• Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients

  2005cited by this paper
• XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.

  2004cited by this paper
• Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study.

  2004cited by this paper
• Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women.

  2004cited by this paper
• Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience.

  2004cited by this paper
• Cholesterol lowering effect of dietary weight loss and orlistat treatment – efficacy and limitations

  2004cited by this paper
• Effects of orlistat on obesity‐related diseases – a six‐month randomized trial

  2004cited by this paper
• Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes

  2004cited by this paper
• Latin‐American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients

  2003cited by this paper
• A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin.

  2003cited by this paper
• Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet.

  2003cited by this paper
• Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double‐blind, randomized, placebo‐controlled trial

  2003cited by this paper
• Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension

  2003cited by this paper
• Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials.

  2003cited by this paper
• Decreasing levels of tumour necrosis factor α and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors

  2003cited by this paper
• Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction.

  2002cited by this paper
• Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors

  2002cited by this paper
• Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study.

  2002cited by this paper
• Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.

  2002cited by this paper
• RANDOMISED TRIAL OF THE EFFECT OF ORLISTAT ON BODY WEIGHT AND CARDIOVASCULAR DISEASE RISK PROFILE IN OBESE PATIENTS: UK MULTIMORBIDITY STUDY

  2002cited by this paper
• New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.

  2002cited by this paper
• Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension

  2002cited by this paper
• Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.

  2002cited by this paper
• Effects of sibutramine on the treatment of obesity in patients with arterial hypertension.

  2002cited by this paper
• Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.

  2001cited by this paper
• Long-term weight loss with sibutramine: a randomized controlled trial.

  2001cited by this paper
• Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X.

  2001cited by this paper
• Principles for enhanced recruitment of subjects in a large clinical trial. the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience.

  2001cited by this paper
• Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over

  2001cited by this paper
• [Sibutramine--antidepressive agent tested against obesity].

  2001cited by this paper
• Influence of sibutramine on energy expenditure in African American women.

  2001cited by this paper
• Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.

  2000cited by this paper
• The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study

  2000cited by this paper
• One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

  2000cited by this paper
• A clinical trial of the use of Sibutramine for the treatment of patients suffering essential obesity

  2000cited by this paper
• Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance.

  2000cited by this paper
• Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial.

  2000cited by this paper
• Orlistat in the long-term treatment of obesity in primary care settings.

  2000cited by this paper
• Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

  2000cited by this paper
• Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.

  1999cited by this paper
• Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine.

  1999cited by this paper
• Absence of cardiac valve dysfunction in obese patients treated with sibutramine.

  1999cited by this paper

• Online HPLC-FLD recognition system drives activity-guided progressive separation to discover pancreatic lipase inhibitors from Sinacalia tangutica

  2026cites this paper
• A New Era in the Medical Management of Obesity.

  2026cites this paper
• Obesity-Driven Hypertension: Exploring the Mechanisms and Modern Treatment Strategies.

  2026cites this paper
• Comparative effectiveness of weight loss interventions on blood pressure in obese patients with hypertension: a protocol for a systematic review and network meta-analysis

  2026cites this paper
• Obesity and its management in primary care setting.

  2025cites this paper
• Polyphenols From Mallotus peltatus (Geiseler) Mull. Arg. Ameliorates FFA‐Induced Hepatic Steatosis in L02 Cells and Reduces Lipid Accumulation in Caenorhabditis elegans

  2025cites this paper
• The effect of meal replacements therapy on blood pressure and C-reactive protein: a systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2025cites this paper
• Interdisziplinäre S3-Leitlinie zur „Prävention und Therapie der Adipositas“ der Deutschen Adipositas-Gesellschaft (DAG) – Überblick über die Empfehlungen zu den Themen „Stigmatisierung“, „Diagnostik“ und „Therapie“

  2025cites this paper
• Efficacy of orlistat in type 2 diabetes: a systematic review and meta-analysis

  2025cites this paper
• Obesity and Hypertension: Etiology and the Effects of Diet, Bariatric Surgery, and Antiobesity Drugs.

  2025cites this paper
• Cardiovascular effects of anti-obesity medications: the perils and promise

  2025cites this paper
• Mechanisms and treatment of obesity-related hypertension—Part 2: Treatments

  2025influential citation
• Long-Term Efficacy and Safety of Nutritional and Pharmacological Strategies for Obesity

  2025cites this paper
• Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity

  2025cites this paper
• Prevention and intervention against obesity and overweight in the military: a systematic review

  2025cites this paper
• American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease - 2025 Update.

  2025cites this paper
• 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2025cites this paper
• What is the evidence regarding the safety of new obesity pharmacotherapies

  2024cites this paper
• Revised definition of obesity in Asian Indians living in India.

  2024cites this paper
• Clinical practice guideline for the management of hypertension in China

  2024cites this paper
• Lifestyle modifications and non-pharmacological management in elderly hypertension.

  2024cites this paper
• 2024 ESC Guidelines for the management of elevated blood pressure and hypertension.

  2024cites this paper
• 2024 Latin American Society of Hypertension guidelines on the management of arterial hypertension and related comorbidities in Latin America.

  2024cites this paper
• A review on drug repurposing applicable to obesity

  2024cites this paper
• GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review

  2024cites this paper
• Current options in obesity pharmacotherapy for children and adolescents

  2024cites this paper
• Freeze-dried biotics based on Lactiplantibacillus plantarum and Lactiplantibacillus paraplantarum with enhanced selected biological activity

  2024cites this paper
• Effectiveness and safety of drugs for obesity

  2024cites this paper
• ASSESSMENT AND MANAGEMENT OF PATIENTS WITH OBESITY AND HYPERTENSION IN EUROPEAN SOCIETY OF HYPERTENSION EXCELLENCE CENTRES. A SURVEY FROM THE ESH WORKING GROUP ON DIABETES AND META

  2024cites this paper
• Identification of pancreatic lipase inhibitors from Eucommia ulmoides tea by affinity-ultrafiltration combined UPLC-Orbitrap MS and in vitro validation.

  2023cites this paper
• Large area fractional laser treatment of mouse skin increases energy expenditure

  2023cites this paper
• Effects of an oral biodegradable device used for 12 weeks on weight reduction, cardiovascular risk factors, satiety, snacking, and meal size

  2023cites this paper
• Development and Validation of Gas Chromatography–Mass Spectrometry Method for Quantification of Sibutramine in Dietary Supplements

  2023cites this paper
• Clinical considerations and pathophysiological associations among obesity, weight loss, heart failure, and hypertension

  2023cites this paper
• Achievement rate of target blood pressure in patients with hypertension treated by hypertension specialists and non-specialists in a real-world setting

  2023cites this paper
• 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH).

  2023cites this paper
• Optimizing glycation control in diabetes: An integrated approach for inhibiting nonenzymatic glycation reactions of biological macromolecules.

  2023cites this paper
• Antidiabetic and Hypolipidemic Properties of Newly Isolated Wild Lacticaseibacillus paracasei Strains in Mature Adipocytes

  2023cites this paper
• Effect of weight loss on blood pressure changes in overweight patients: A systematic review and meta‐analysis

  2023cites this paper
• Anti-Adipogenic and Anti-Obesity Effects of Gongmi Tea and Gongmi So Extract

  2023cites this paper
• Compliance to Multidisciplinary Lifestyle Intervention Decreases Blood Pressure in Patients with Resistant Hypertension: A Cross-Sectional Pilot Study

  2023cites this paper
• The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis

  2023cites this paper
• Intragastric Balloon Significantly Improves Metabolic Parameters at 6 Months: a Meta-Analysis

  2023cites this paper
• Off-label drugs for obesity

  2022cites this paper
• Nutrition and blood pressure

  2022cites this paper
• In vivo activities of the structured lipids -1, 3-dioleic acid 2-palmitic acid triglyceride (OPO) in high-fat diet mice

  2022cites this paper
• Piperine attenuates hepatic steatosis and insulin resistance in high-fat diet-induced obesity in Sprague-Dawley rats.

  2022cites this paper
• Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs)

  2022cites this paper
• Brevibacillus laterosporus BL1, a promising probiotic, prevents obesity and modulates gut microbiota in mice fed a high-fat diet

  2022cites this paper
• The Role of Medicinal and Aromatic Plants against Obesity and Arthritis: A Review

  2022cites this paper
• Nipsnap1—A regulatory factor required for long-term maintenance of non-shivering thermogenesis

  2022cites this paper
• Inhalation of low-dose basil (Ocimum basilicum) essential oil improved cardiovascular health and plasma lipid markers in high fat diet-induced obese rats.

  2022cites this paper
• Pharmacotherapy for adults with overweight and obesity.

  2022cites this paper
• A narrative review of anti-obesity medications for obese patients with osteoarthritis

  2022cites this paper
• Therapeutics for rheumatic fever and rheumatic heart disease

  2022cites this paper
• Screening of lipase inhibitors in citrus fruits by electrophoresis - mediated microanalysis combined with molecular docking

  2021cites this paper
• Obesity Management of Liver Transplant Waitlist Candidates and Recipients.

  2021cites this paper
• Long-term effects of weight-reducing drugs in people with hypertension.

  2021cites this paper
• Long-term effects of weight-reducing diets in people with hypertension.

  2021cites this paper
• Sibutramine as a Cause of Sudden Cardiac Death

  2021cites this paper
• Effect of Panax notoginseng Saponins and Major Anti-Obesity Components on Weight Loss

  2021cites this paper
• Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta‐Analysis

  2021cites this paper
• For adults with obesity and hypertension, what are the long-term effects of orlistat or naltrexone/bupropion?

  2021cites this paper
• Long-term cardiovascular outcomes after orlistat therapy in patients with obesity: a nationwide, propensity-score matched cohort study.

  2021cites this paper
• Obesity Management in Cardiometabolic Disease: State of the Art

  2021cites this paper
• Weight-Loss Strategies for Prevention and Treatment of Hypertension: A Scientific Statement From the American Heart Association

  2021cites this paper
• New Incretin Combination Treatments under Investigation in Obesity and Metabolism: A Systematic Review

  2021cites this paper
• The role of body mass index in the association between dietary sodium intake and blood pressure: A mediation analysis with NHANES.

  2021cites this paper
• Anti-Obesity Effect of Polygalin C Isolated from Polygala japonica Houtt. via Suppression of the Adipogenic and Lipogenic Factors in 3T3-L1 Adipocytes

  2021cites this paper
• Pharmacotherapy of obesity in complex diseases

  2021cites this paper
• Cyanidin-3-O-glucoside Regulates the Expression of Ucp1 in Brown Adipose Tissue by Activating Prdm16 Gene

  2021cites this paper
• Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon‐Like Peptide‐1 Receptor Agonist and Sodium‐Glucose Cotransporter‐2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta‐Analysis

  2020cites this paper
• Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery.

  2020cites this paper
• Reganancia de peso tras cirugía bariátrica en pacientes diabéticos en un hospital universitario de argentina

  2020cites this paper
• Arterieller Hypertonus und Adipositas // Arterial hypertension and obesity

  2020cites this paper
• A review on the current drugs and new targets for obesity

  2020cites this paper
• Efficacy and safety of phentermine/topiramate in adults with overweight or obesity: A meta-analysis and systematic review

  2020cites this paper
• Hypertension and Heart Failure: Epidemiology, Mechanisms and Treatment

  2020cites this paper
• Current and investigational anti-obesity drugs help reduce weight and offer additional benefits, but more effective options are needed

  2020cites this paper
• Cardiovascular Risks and Benefits of Medications Used for Weight Loss

  2020cites this paper
• Endoscopic Treatments for Obesity: The Good, the Bad, and the Ugly.

  2020cites this paper
• The limits and challenges of antiobesity pharmacotherapy.

  2020cites this paper
• Critical review of nutrition, blood pressure and risk of hypertension through the lifecycle: do B vitamins play a role?

  2020cites this paper
• In people with hypertension, what are the long-term effects of orlistat?

  2019cites this paper
• Current and investigational anti-obesity drugs help reduce weight and offer additional benefits, but more effective options are needed

  2019cites this paper
• Drugs and Supplements for Weight Reduction

  2019cites this paper
• Excluding non-English publications from evidence-syntheses did not change conclusions: a meta-epidemiological study.

  2019cites this paper
• A 28-Day Carbohydrate-Restricted Diet Improves Markers of Cardiometabolic Health and Performance in Professional Firefighters.

  2019cites this paper
• Short-Term Evidence in Adults of Anorexigenic Drugs Acting in the Central Nervous System: A Meta-Analysis.

  2019cites this paper
• Weight Loss and Hypertension in Obese Subjects

  2019cites this paper
• Antiobesity effects of anthocyanins on mitochondrial biogenesis, inflammation, and oxidative stress: A systematic review.

  2019cites this paper
• Wpływ kanabinoidów na układ wydzielania wewnętrznego

  2019cites this paper
• Treatment: New Drugs

  2019cites this paper
• Pharmacotherapy of Obesity: Limits and Perspectives

  2019cites this paper
• Weight Loss Medications in the Treatment of Obesity and Hypertension

  2019cites this paper
• Prehypertension and Cardiometabolic Syndrome

  2019cites this paper
• Pharmacotherapy of obesity: Available medications and drugs under investigation.

  2019cites this paper
• Chrysanthemum indicum Inhibits Adipogenesis and Activates the AMPK Pathway in High-Fat-Diet-Induced Obese Mice.

  2018cites this paper
• Chrysanthemum indicum L. ethanol extract reduces high-fat diet-induced obesity in mice.

  2018cites this paper